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Background: Mediastinitis is a severe complication after cardiac surgery. While improvement of prophylaxis and of
medical and surgical therapy has reduced its incidence, the treatment of mediastinitis continues to be a
challenging problem. Within this study, we report the successful use of daptomycin as supportive therapy in
patients developing mediastinitis after open cardiac surgery.
Methods: The records of 21 consecutive patients who developed mediastinitis after cardiac surgery were
retrospectively reviewed. After diagnosis, all patients received surgical debridement and antibiotic therapy with
daptomycin. All patients were followed up to death or discharge.
Results: Clinical improvement after combined surgical and antibiotic therapy with daptomycin was found in 90.5%
of the patients. The median time until clinical improvement occurred was 5 [4/6] days. Daptomycin was well-tolerated
and no major adverse events during therapy were observed observed.
Conclusions: This study provides new and helpful information regarding the beneficial use of daptomycin as supportive
treatment option in patients developing mediastinitis after cardiac surgery.
Keywords: Mediastinitis, Cardiac surgery, DaptomycinBackground
Sternal wound infection after cardiac surgery is a serious
and potentially life-threatening complication. The exact
pathologic mechanism underlying this infection remains
unclear; patients’ pre-operative co-morbidities, as obes-
ity, diabetes, peripheral arterial disease or chronic ob-
structive pulmonary disease may play an important role
[1,2].
In up to 5% of patients undergoing sternotomy, med-
iastinitis occurs after surgery [3]. Mediastinitis is asso-
ciated with high in-hospital [4] and long-term mortality
rates and significant additional costs [5]. The treatment
of mediastinitis usually consists of combined surgical
and antibiotic [6]. So far, newly developed antibiotics* Correspondence: Jens.Heyn@med.uni-muenchen.de
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reproduction in any medium, provided the orhave not been evaluated regarding their effects as sup-
portive treatment option to surgical debridement [7].
Daptomycin (Cubicin©, Novartis Pharma AG, Nuremberg,
Germany), a cyclic lipopeptide antibiotic, is a newly and use-
ful drug against infections with multidrug-resistant gram-
positive organisms. Daptomycin has been successfully used
in the treatment of endocarditis and complicated cardiac de-
vice infections [8]. We report the beneficial use of daptomy-
cin as supportive traetment option to surgical debridement
in 21 patients who developed mediastinitis after cardiac
surgery.Methods
We retrospectively reviewed the records of 21 consecu-
tive patients who developed mediastinitis after cardiac
surgery followed by combined surgical debridement and
antibiotic therapy with daptomycin. During initial oper-
ation, the included patients received 3 x 1.5 g Cefuroxime
as antibiotic prophylaxis.d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 2 Primary heart surgery prior to mediastinal
infection
Primary heart surgery Number (%)
Aortic valve replacement 5 (23.8)
Coronary artery bypass 4 (19.0)
Heart transplantation 3 (14.3)
Left ventricular assist device 3 (14.3)
Biventricular assist device 2 (9.5)
Mitral valve repair 2 (9.5)
Implantation of a defibrillator 2 (9.5)
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of clinical assessment, CT-scans, laboratory values, and
microbiologic analysis. In the circumstances of mediasti-
nitis, the patients usually developed fever, tachycardia,
and leucocytosis. In addition to the responsible microor-
ganisms, we analysed laboratory findings, risk factors,
drug compatibility, and the outcome.
All patients underwent aggressive surgical exploration
followed by the closed irrigation technique (CIT) and
received daptomycin intravenously (initial dosage of
6 mg/kg on the first day and 4 mg/kg, the following
days). CIT consists of wound debridement, sternal
stabilization and closed irrigation of the mediastinum
and pericardium with saline or antiseptic solutions.
Sternal refixation occurred mostly using a Robicsek
technique as described before [9]. Tissue cultures and
cutaneous swabs were obtained in all patients during
operation.
The patients were followed up to either death or dis-
charge. Therapy was considered unsuccessful if recur-
rence of infection occurred, indicated by persistent
purulent secretion and wound dehiscence.
Statistical descriptive analyses of the results were
expressed as median and 25th to 75th percentile or as
numbers with related percentage. All analyses were per-
formed using SPSS software (version 15.1 for Windows,
SPSS, Inc, Chicago, Ill, USA).
Results
21 patients developed mediastinitis after cardiac surgery.
These patients had a median age of 66 [56.5/76] years. 20
of the patients (95.2%) were male and 1 patient (4.8%)
was female. Risk factors for wound complications were
similar to those reported by others [10]. Six patients
(28.6%) were diabetic and required either insulin or oral
agents, seven patients had chronic renal failure (33.3%),
and two patients (9.5%) showed COPD pre-operatively
(Table 1). The median BMI of these patients was 24.7
[23.2/27.8]. 10 of the included patients received corticos-
teroids (8 patients received hydrocortisone and 2 patients
prednisolone due to organ transplantation).Table 1 Preoperative risk factors for mediastinitis after
cardiac surgery
Risk factors Number (%)
Mitral regurgitation 13 (61.9)
Peripheral vascular disease 12 (57.1)
Aortic stenosis 7 (33.3)
Dialysis dependent renal insufficiency 7 (33.3)
Diabetes 6 (28.6)
Internal mammary artery bypass 3 (14.3)
Chronic obstructive pulmonary disease 2 (9.5)Procedures performed included aortic valve replace-
ment (5 patients), coronary artery bypass (4 patients),
heart transplantation (3 patients), left ventricular assist
device (3 patients), biventricular assist device (2 patients),
mitral valve repair (2 patients), and implantation of a defib-
rillator (2 patients). The Berlin Heart ExcorW (Berlin Heart,
Berlin, Germany) was used as ventricular assist device.
(Table 2).
Diagnosis was established by smear, blood cultures, CT-
scan and clinical symptoms. Microbiological evaluation of
these samples revealed Staphylococcus aureus (8 patients),
various gram-positive organisms (5 patients), Enterococcus
faecium (3 patient), and methicillin-resistant Staphylococ-
cus aureus (MRSA – 3 patients). A pathogen could not be
identified in 2 patients, due to the fact that antibiotic ther-
apy was initiated after the appearance of first symptoms
and before the diagnosis of mediastinitis was established
(Table 3). These two patients died during the hospital stay
because of sepsis and multi-organ failure related to severe
infection. In 14 cases (66.7%) the pathogen was only sens-
ible to vancomycin, linezolid or daptomycin.
All patients underwent surgical debridement com-
bined with drainage in 5 patients and removal of the
implanted device in 4 patients. The removed devices
were implantable cardioverter defibrillators; ventricular
assist devices had not to be removed. Microbiological
analysis of the removed materiel did not show any bac-
teriological population.
Surgical debridement was combined with calculated
antibiotic therapy. Therapy was initiated with ureidope-
nicillins (in 9 cases as monotherapy and in 6 cases asTable 3 Organisms causing the mediastinitis
Organism associated with mediastinitis Number (%)
Staphylococcus aureus 8 (38.1)
Gram-positive organisms 5 (23.8)
Enterococcus faecium 3 (14.3)
MRSA 3 (14.3)
No germ isolated 2 (9.5)
Table 4 Clinical alteration after therapy with daptomycin
Therapeutical success Number (%)
Healing without residues 17 (81.0)
Healing with residues 2 (9.5)
Unsuccessful 2 (9.5)
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therapy and in 12 cases as combined therapy), cephalos-
porins (in 3 cases as combined therapy), or others
(in 11 cases as combined therapy). Antibiotic therapy
was changed to Daptomycin in all patients after 2
[1/3] days according to the antibiogram or in cases of
disease progression.
Clinical improvement after therapy with daptomycin
was detected in 90.5%; in 17 patients (81%) eradication
without residues was achieved, in two patients (9.5%)
eradication with residues was detected, and in two
patients the therapy was unsuccessful (Table 4). The me-
dian until clinical improvement occurred was 5 [4/6]
days. During therapy, daptomycin lead to mild increase
in creatinine kinase, and values of leukocytes. These
increased values declined distinctly after therapy
(Figure 1 and Figure 2). No major adverse events during
antibiotic therapy with daptomycin were detected; only a
mild allergic reaction occurred in a single case. Median
duration of daptomycin therapy was 8.5 [7/15] days.Discussion
In spite of improvements in surgical techniques and
medical therapy, the frequency of mediastinitis has
remained stable during the last years [11]. Therefore,
therapy of mediastinitis after cardiothoracic surgery













Figure 1 Creatine Kinase (CK) values before, during and after therapyStaphylococcus aureus is the most common isolated
germ in patients developing mediastinitis [12]. Unfor-
tunately, Staphylococcus aureus has become an evolv-
ing management problem, because of an increasing
number of antibiotic resistance and MRSA infections
which causes high rates of morbidity and mortality
[12,13].
Vancomycin is still the antibiotic therapy of choice
for the treatment of infections caused by MRSA.
However, the therapy with vancomycin may be con-
traindicated in a number of cases (e.g. renale failure)
and ineffective in numerous cases because of limited
tissue penetration [14]. Furthermore, Staphylococcus
aureus (including MRSA) exhibits a declining suscep-
tibility to vancomycin during the last years [15]. Thus,
the need for alternative antibiotic therapies as sup-
portive therapy after surgical debridement has become
apparent [15].
An alternative antibiotic option seems to be linezolid,
because linezolid eradicates MRSA better than vanco-
mycin in complicated skin or soft-tissue infections
caused by MRSA. Furthermore, linezolid reduces the
length of hospitalization in these patients [16]. Despite
the advantages of linezolid, concerns about safety and
costs often limit its use.
Daptomycin is a cyclic lipopeptide antibiotic with bac-
tericidal activity against gram-positive organisms in a
concentration-dependent manner [8]. In patients with
(gram-positive) wound infection, daptomycin is useful in
more than 90% [17] which is comparable to success
rates found for vancomycin (87%) and linezolid (93%).
Furthermore, eradication of bacterial infections by dap-
tomycin amounts 96% in the case of MRSA, 92% in the
case of coagulase-negative staphylococci, and 88% in the






























Figure 2 Leucocyte values before, during and after therapy with daptomycin.
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pharmacokinetic profile of this drug. Daptomycin exhi-
bits excellent penetration of subcutaneous tissue levels
in healthy volunteers (averaging 74% of plasma levels)
and inflammatory tissues (averaging nearly 70% of
plasma levels) [17]. Although daptomycin penetrates the
tissue rapidly, disappearance is relatively slow, with an
elimination half-life of more than 17 hours [6,16,17].
Daptomycin is highly effective in the treatment of bac-
teraemia and endocarditis caused by MRSA and several
reports document its effectiveness in infections related
to cardiac surgery [8,18]. Based on these observations,
we analysed the role of daptomycin as new treatment
option as supportive treatment to surgical therapy in
patients developing mediastinitis after cardiac surgery.
Within our study, we found clinical success in more
than 90% when daptomycin was combined with surgical
therapy. The patients responded to daptomycin therapy
commonly after 5 days. Daptomycin was well tolerated
in the present study which is in accordance to previous
studies. The patients may benefit by the fact, that dapto-
mycin is able to penetrate into device-adhering biofilms
better than other antibiotics [6]. However, controlled
prospective studies are necessary to evaluate the optimal
surgical and antibiotic regime in these patients
Conclusion
This study provides new and helpful information regard-
ing the beneficial use of daptomycin as supportive treat-
ment option in patients developing mediastinitis after
cardiac surgery.
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